Latest ankylosing spondylitis Stories
Health Canada is warning consumers not to use the prescription drug piroxicam to treat short-term pain and inflammation because of safety risks. The federal agency said it has conducted a safety review of the drug and concluded piroxicam causes an increased risk of serious skin reactions and gastrointestinal
A new study by The George Institute for International Health has found Tai Chi to have positive health benefits for musculoskeletal pain. The results of the first comprehensive analysis of Tai Chi suggest that it produces positive effects for improving pain and disability among arthritis sufferers.
The beneficial effects of pregnancy and childbearing on arthritic conditions may be more long-term than previously thought, Norwegian researchers said. Dr.
After five years of receiving infliximab (IFX) anti-TNF therapy, 61.8% of patients with ankylosing spondylitis (AS) showed substantial clinical benefit (ASAS40, ASsessment in AS, 40-response) and 27.6% achieved ASAS partial remission.
Nulliparous women (those who have not given birth to children) are diagnosed with chronic arthritides (including ankylosing spondylitis, psoriatic arthritis and rheumatoid arthritis (RA) an average of 5.2 years before parous women (those who have given birth to children), according to a new study presented today at EULAR 2009
Long-Term Data in Patients Receiving Every-Four-Week Subcutaneous SIMPONI Presented at 2009 EULAR Annual Congress COPENHAGEN, June 9 /PRNewswire/ -- Findings from open-labeled, uncontrolled extensions of two randomized, placebo-controlled Phase 3 studies showed that subcutaneous (SC) injections of SIMPONI(TM) (golimumab) 50 mg or 100 mg every four weeks provided persistent improvements in the signs and symptoms in patients with psoriatic arthritis (PsA) and ankylosing spondylitis (AS).
EXTON, Pa., April 27 /PRNewswire/ -- BioTrends is pleased to announce the fielding of a new syndicated report, LaunchTrends(TM): SIMPONI(R). Cenotcor Ortho Biotech, Inc. announced that they received FDA approval for SIMPONI(R) (generic name: golimumab) on April 24, 2009.
The U.S. Food and Drug Administration says it has approved Simponi, a monthly injectable treatment for three types of arthritis. The FDA said Simponi (golimumab) was approved for use by adults with moderate-to-severe rheumatoid arthritis, active psoriatic arthritis and active ankylosing spondylitis.
- The second approved antibody generated from Medarex's UltiMAb(R) technology platform - PRINCETON, N.J., April 14 /PRNewswire-FirstCall/ -- Medarex, Inc.
Canadian Approval Is World's First Regulatory Approval for SIMPONI HORSHAM, Pa. and KENILWORTH, N.J., April 13 /PRNewswire-FirstCall/ Centocor Ortho Biotech Inc.
- A ceramic container used inside a fuel-fired kiln to protect pots from the flame.